During the past decades, the wider application of easily available haploidentical donor
hematopoietic cell transplant (haplo-HCT) has been made possible through the T cell-replete
(TCR) regimens including T cell regulation with anti-thymocyte globulin (ATG)/granulocyte
colony-stimulating factor (GCSF) and post-transplant cyclophosphamide (PTCy). To achieve
decreased non-relapse mortality (NRM) and improved long-term outcomes in haploidentical
transplant, the joint use of ATG and PTCy might effectively reduce graft versus host disease
(GVHD) and mortality associated with severe forms of GVHD. Recently, investigators
established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to
lower the risk of GVHD without compromising engraftment and disease relapse.